Leukoencephalopathy is a hallmark of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) a devastating disorder characterized by ptosis, ophthalmoparesis, gastrointestinal dysfunction and polyneuropathy. To characterize MNGIE-associated leukoencephalopathy and to correlate it with clinical, biochemical and molecular data, four MNGIE patients with heterogeneous clinical phenotypes (enteropathic arthritis, exercise intolerance, CIDP-like phenotype and typical presentation) were studied by magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Diffusion weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps were also obtained. In two patients we also investigated the role of brain MRI in monitoring the evolution of leukoencephalopathy by performing follow-up imaging studies at an interval of one and two years. The extension and distribution of leukoencephalopathy were not clearly linked with age, phenotype or disease severity, and did not seem to be related to TYMP mutations, enzyme activity or pyrimidine levels. In the studied patients MRS revealed reduced N-acetyl-aspartate and increased choline signals. Although DWI appeared normal in all patients but one, ADC maps always showed moderate increased diffusivity. Leukoencephalopathy worsened over a two-year period in two patients, regardless of the clinical course, indicating a lack of correlation between clinical phenotype, size and progression of white matter abnormalities during this period. Brain MRI should be considered a very useful tool to diagnose both classical and atypical MNGIE. Serial MRIs in untreated and treated MNGIE patients will help to establish whether the leukoencephalopathy is a reversible condition or not.
NishinoISpinazzolaAHiranoM. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 1999; 283: 689–692.
2.
LaraMCValentinoMLTorres-TorronterasJ. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci Rep.2007; 27: 151–163.
3.
GaroneCTadesseSHiranoM. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2011; 134: 3326–3332.
4.
MartíRVerschuurenJJBuchmanA. Late-onset MNGIE due to partial loss of thymidine phosphorylase activity. Ann Neurol. 2005; 58: 649–652.
5.
HiranoMSilvestriGBlakeDM. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology. 1994; 44: 721–727.
6.
HiranoMNishigakiYMartiR. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a disease of two genomes. Neurologist. 2004; 10: 8–17.
7.
MartínMABlázquezAMartíR. Lack of gastrointestinal symptoms in a 60-year-old patient with MNGIE. Neurology. 2004; 63: 1536–1537.
8.
MassaRTessaAMargollicciM. Late-onset MNGIE without peripheral neuropathy due to incomplete loss of thymidine phosphorylase activity. Neuromuscul Disord. 2009; 19: 837–840.
MillarWSLignelliAHiranoM. MRI of five patients with mitochondrial neurogastrointestinal encephalomyopathy. Am J Roentgenol. 2004; 182: 1537–1541.
12.
Barragán-CamposHMValléeJLôD. Brain magnetic resonance imaging findings in patients with mitochondrial cytopathies. Arch Neurol. 2005; 62: 737–742.
13.
ScagliaFWongL-JCVladutiuGD. Predominant cerebellar volume loss as a neuroradiologic feature of pediatric respiratory chain defects. Am J Neuroradiol. 2005; 26: 1675–1680.
Carod-ArtalFJHerreroMDLaraMC. Cognitive dysfunction and hypogonadotrophic hypogonadism in a Brazilian patient with mitochondrial neurogastrointestinal encephalomyopathy and a novel ECGF1 mutation. Eur J Neurol. 2007; 14: 581–585.
16.
DiogoLCordeiroMGarciaP. Value of brain magnetic resonance imaging in mitochondrial respiratory chain disorders. Pediatr Neurol. 2010; 42: 196–200.
17.
FriedmanSDShawDWIshakG. The use of neuroimaging in the diagnosis of mitochondrial disease. Dev Disabil Res Rev.2010; 16: 129–135.
18.
FinstererJZarrouk MahjoubS. Leukoencephalopathies in mitochondrial disorders: clinical and MRI Findings. J Neuroimaging. 2012; 22: e1–11.
19.
Lerman-SagieTLeshinsky-SilverEWatembergN. White matter involvement in mitochondrial diseases. Mol Gen Metab2005; 84: 127–136.
20.
SalsanoEFarinaLLampertiC. Adult-onset leukodystrophies from respiratory chain disorders: do they exist?J Neurol. 2013; 260: 1617–1623.
21.
BianchiMCTosettiMBattiniR. Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance. Am J Neuroradiol. 2003; 24: 1958–1966.
22.
UrenjakJWilliamsSRGadianDG. Proton nuclear magnetic resonance spectroscopy unambigously identifies different neuronal cell types. J Neurosci. 1993; 13: 981–989.
23.
Vion-DuryJNicoliPSalvanAM. Reversal of brain metabolic alterations with zidovudine detected by proton localized magnetic resonance spectroscopy. Lancet. 1995; 345: 60–61.
24.
FinstererJ. Central nervous system imaging in mitochondrial disorders. Can J Neurol Sci.2009; 36: 143–153.
25.
BarkovichAJ. Magnetic resonance techniques in the assessment of myelin and myelination. J Inherit Metab Dis.2005; 28: 311–343.
26.
PadmaMVAdinehMPugarK. Functional imaging of a large demyelinating lesion. J Clin Neurosci. 2005; 12: 176–178.
27.
FilostoMScarpelliMToninP. Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol. 2012; 259: 2699–2706.
28.
HalterJSchüpbachWMCasaliC. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant. 2011; 46: 330–337.
ScarpelliMRussignanAZomborM. Poor outcome in a mitochondrial neurogastrointestinal encephalomyopathy patient with a novel TYMP mutation: the need for early diagnosis. Case Rep Neurol. 2012; 4: 248–253.
31.
ShaibaniAShchelochkovOAZhangS. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol. 2009; 66: 1028–1032.
32.
Van GoethemGSchwartzMLofgrenA. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet. 2003; 11: 547–549.
33.
TangSDimbergELMiloneM. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations. J Neurol. 2012; 259: 862–868.
34.
HorváthRBenderAAbichtA. Heteroplasmic mutation in the anticodon-stem of mitochondrial tRNA(Val) causing MNGIE-like gastrointestinal dysmotility and cachexia. J Neurol. 2009; 256: 810–815.
35.
SchüpbachWMMVaddayKMSchallerA. Mitochondrial neurogastrointestinal encephalomyopathy in three siblings: clinical, genetic and neuroradiological features. J Neurol. 2007; 254: 146–153.
SimonLHoroupianDDorfmanL. Polyneuropathy, ophthalmoplegia, leukoencephalopathy and intestinal pseudo-obstruction: POLIP syndrome. Ann Neurol. 1990; 28: 349–360.
38.
BardosiACreutzfeldtWDiMauroS. Myo-neurogastrointestinal encephalopathy (MNGIE syndrome) due to partial deficiency of cytochrome c oxidase: a new mitochondrial multisystem disorder. Acta Neuropathol (Berl). 1987; 74: 248–258.
39.
SzigetiKSuleNAdesinaAM. Increased blood-brain barrier permeability with thymidine phosphorylase deficiency. Ann Neurol. 2004; 56: 881–886.
40.
LópezLCAkmanHOGarcía-CazorlaA. Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. Hum Mol Genet. 2009; 18: 714–722.
41.
HiwatashiAZhongJ. Pitfalls and artifacts of DW imaging. In: MoritaniTEkholmSWestessonPL, eds. Diffusion-weighted MR imaging of the brain. New York: Springer-Verlag. 2005; p. 11–24.
42.
CaseyS. “T2 washout”: an explanation for normal diffusion weighted images despite abnormal apparent diffusion coefficient maps. Am J Neuroradiol. 2001; 22: 1450–1451.
43.
ProvenzaleJMPetrellaJRCruzLCJr. Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. Am J Neuroradiol. 2001; 22: 1455–1461.
